US FDA panel to review approach to checkpoint blockers

The US Food and Drug Administration (FDA) has scheduled a public meeting of key scientific advisors to discuss the use of predictive biomarkers for immune checkpoint inhibitors.

The Oncologic Drugs Advisory Committee (ODAC) will meet on 26 September to consider the risk-benefit balance of PD-L1 expression level cutoffs in treating advanced gastric and esophageal cancers.

The outcome of the meeting could be significant, with the panel’s findings likely to influence future regulatory decisions in this area.